For these reasons, it is the most widely used diagnostic test for RSV. RADTs are rapid immunoassays and are available from a variety of manufacturers in ready-made commercialized kits. With one ...
News Medical on MSN1d
Real world data highlights effectiveness of RSV vaccineA multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV -- ...
Cold and flu season — otherwise known as mid-October — is upon us. But this year, several advancements in vaccines could help families keep viruses at bay. One of the new developments is a ...
For some folks, the fall to-do list should now include an important third jab—a respiratory syncytial virus (RSV) vaccine. (The FDA approved the first one in 2023.) While flu and COVID cases ...
RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren't as worried about it anymore. RSV is common but can be dangerous ...
RSV vaccines hold the potential to reduce the thousands of hospitalizations and deaths associated with the virus in the US each year. But vaccines are only effective if they get in the arms of the ...
GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated AReSVi 006 trial in adults ...
We collected the following information for each patient from the electronic medical record: age, sex, length of stay, race, insurance information, RSV laboratory test results and gestational age ...
More than a dozen Toronto schools have signed up for “spit kits,” a Hospital for ... that opportunity to be able to test not only for COVID but also RSV and influenza, I hoped that my ...
Rates of SUID per 100,000 live births rose by 10% from 2019 to 2021. A rise in rates of sudden unexpected infant deaths may have been linked to an off-season surge of respiratory syncytial virus ...
Today, we talk about some RSV competition that’s brewing, how Alnylam’s CEO spoke about its plans with ATTR-CM, and more. Alnylam Pharmaceuticals is expanding the footprint of its RNA-based ...
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback